Nasal lesions induced by intranasal administration of benzaikonium chloride in rats.
We investigated the lesions of nasal cavity mucous membrane caused by administration of 0.01, 0.05 and 0.10 w/v% Benzalkonium chloride (BZC) solutions in the nasal cavity of rats. No BZC-induced symptoms or nasal lesions were seen in the 0.01 w/v% BZC-treated group. On the other hand, BZC-induced symptoms such as nasal sound and rubbing the nose with forelegs were observed in the 0.05 and 0.10 w/v% BZC-treated groups. Additionally, BZC-induced lesions, including epithelial desquamation, inflammation and edema, occurred in the anterior nasal cavity in the 0.05 and 0.10 w/v% BZC-treated groups, but these lesions were confined to the dorsal meatus and the adjacent nasal septum. These results indicate that 0.01 w/v% BZC solution has no effect on the nasal cavity mucous membrane. However, 0.05 and 0.10 w/v% BZC solutions induce lesions in the nasal cavity mucous membrane due to their irritating effect.
Kuboyama
Y
Y
Toxicological Research Laboratories, Kyowa Hakko Kogyo Co., Ltd., Yamaguchi, Japan.
Suzuki
K
K
Hara
T
T
D000281:Administration, Intranasal; D000818:Animals; D000891:Anti-Infective Agents, Local / Q000008:administration & dosage / Q000633:toxicity*; D001548:Benzalkonium Compounds / Q000008:administration & dosage / Q000633:toxicity*; D004487:Edema / Q000139:chemically induced; D004848:Epithelium / Q000187:drug effects / Q000473:pathology; D007249:Inflammation / Q000139:chemically induced; D008297:Male; D009092:Mucous Membrane / Q000187:drug effects / Q000473:pathology; D009296:Nasal Cavity / Q000187:drug effects* / Q000473:pathology; D011310:Preservatives, Pharmaceutical / Q000008:administration & dosage / Q000633:toxicity*; D051381:Rats; D017208:Rats, Wistar; D016707:Tissue Fixation
D000891:Anti-Infective Agents, Local; D001548:Benzalkonium Compounds; D011310:Preservatives, Pharmaceutical